Yazar "Tan, Turkan Seda" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Evaluation of the Impact of Ranolazine Treatment on Liver Function Tests in Patients With Coronary Heart Disease and Nonalcoholic Fatty Liver Disease
    (Sage Publications Inc, 2022) Esenboga, Kerim; Kurtul, Alparslan; Nazman, Huseyin; Tekin, Cemre Gul; Ozyuncu, Nil; Tan, Turkan Seda; Tutar, Eralp
    Nonalcoholic fatty liver disease (NAFLD) is the most common liver pathology in the developed world. Nonalcoholic fatty liver disease is associated with a higher risk of cardiovascular disease. We investigated the impact of ranolazine on liver tests in patients with NAFLD and coronary artery disease (CAD). Patients who had established CAD and NAFLD (as assessed by raised serum transaminase activity, sonographic criteria, and the absence of any other obvious liver disease) were allocated to on ranolazine (n = 40) or not on ranolazine (n = 35) groups. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured in all patients at baseline and at the end of the study. After 6 months of ranolazine treatment, both ALT and AST activities were significantly lower in patients in the on ranolazine group compared with not on ranolazine patients (change from baseline: ALT, -11.0 +/- 1.7 IU/L, P < .001; AST, -5.2 +/- 1.9 IU/L, P =.009). In conclusion, the present study showed that treatment with ranolazine for 6 months led to a significant reduction in the activities of both serum aminotransferases in patients with stable CAD and NAFLD.
  • Küçük Resim
    Öğe
    Systemic immune-inflammation index predicts no-reflow phenomenon after primary percutaneous coronary intervention
    (Taylor & Francis Ltd, 2022) Esenboga, Kerim; Kurtul, Alparslan; Yamanturk, Yakup Yunus; Tan, Turkan Seda; Tutar, Durmus Eralp
    Objective Systemic immune-inflammation index (SII), on the basis of lymphocyte, neutrophil and platelet counts had been published to be a good prognostic factor in coronary artery disease. Nevertheless, the prognostic value of Systemic immune-inflammation index (SII) in a condition of no-reflow phenomenon (NRP) remains inconsistent, we evaluated the SII as a simple calculated tool for predicting the NRP among patients with STEMI who underwent primary percutaneus coronary intervention (PCI). Method 510 consecutive acute STEMI patients who underwent primary PCI within 12 h from symptom onset from October 2015 to January 2020 were enrolled in our study. The receiver-operating characteristic (ROC) curve was used to determine the cut-off value of SII to predict the no-reflow. Multivariate stepwise logistic regression, including covariates found to have a significant association with NRP in univariate analysis, was used to identify independent predictors of no-reflow. Results A ROC curve analysis showed that the best cut-off value of SII for predicting no-reflow was 1028, with sensitivity and specificity of 79% and 70, respectively (AUC, 0.839; 95% CI 0.797-0.881). An ROC curve comparison analysis was performed to compare the SII with NLR and PLR. Multivariate analysis revealed that SII >= 1028 value (OR = 6.622, 95% confidence interval (CI): 3.802-11.627, p < .001), not using aspirin prior to admission (OR = 0.431, 95%CI: 0.236-0.786, p = .006), and CRP (OR = 1.004, 95%CI: 1.001-1.008, p = .041) were independent predictors related to occurrence of NRP after primary PCI in patients with acute STEMI. Conclusion SII levels are independently associated with the NRP in patients undergoing primary PCI for acute STEMI. High SII may be a promising indicator for the prediction of NRP in these patients.